In the HER2‐positive cohort, 30% of the cancers were ER‐positive/PgR‐positive, 8% were ER‐positive/PgR‐negative, 3% were ER‐negative/PgR‐positive, and 59% were ER‐negative/PgR‐negative. The gene discussed is ERBB2; the disease is cancer.